Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder-Reference-Cited by-同舟云学术

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

Published:2010-05 Issue:5 Volume:57 Page:766-773
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Sylvester Richard J.,Brausi Maurizio A.,Kirkels Wim J.,Hoeltl Wolfgang,Calais Da Silva Fernando,Powell Philip H.,Prescott Stephen,Kirkali Ziya,van de Beek Cees,Gorlia Thierry,de Reijke Theo M.

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder;Babjuk;Eur Urol,2008

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

3. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer;Shelley;BJU Int,2001

4. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity;Bohle;J Urol,2003

5. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer;Malmström;Eur Urol,2009

Cited by 354 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter to the editor: Multiparametric MRI-based VI-RADS: Can it predict 1- to 5-year recurrence of bladder cancer?;European Radiology;2024-08-30

2. Experience of organizing BCG therapy for localized bladder cancer in outpatient cancer care centers;Consilium Medicum;2024-08-30

3. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-22

4. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

5. No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial;Minerva Urology and Nephrology;2024-07